ProKidney (ProKidney) Ending Cash Position : $84.39 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney Ending Cash Position?

ProKidney's Ending Cash Position for the quarter that ended in Mar. 2024 was $84.39 Mil.

ProKidney's quarterly Ending Cash Position declined from Sep. 2023 ($191.39 Mil) to Dec. 2023 ($60.65 Mil) but then increased from Dec. 2023 ($60.65 Mil) to Mar. 2024 ($84.39 Mil).

ProKidney's annual Ending Cash Position increased from Dec. 2021 ($20.56 Mil) to Dec. 2022 ($490.25 Mil) but then declined from Dec. 2022 ($490.25 Mil) to Dec. 2023 ($60.65 Mil).

ProKidney Ending Cash Position Historical Data

The historical data trend for ProKidney's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Ending Cash Position Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

4.58

20.56

490.25

60.65

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial									271.64	243.55	191.39	60.65	84.39

ProKidney Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ProKidney's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	490.252	+	-429.603
	=	60.65

ProKidney's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	60.649	+	23.74
	=	84.39

ProKidney Ending Cash Position Related Terms

Thank you for viewing the detailed overview of ProKidney's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney (ProKidney) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

PROK:Mexico

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.

Executives

Chamath Palihapitiya	10 percent owner	THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Sc Pipe Holdings Llc	10 percent owner	506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025
Sc Master Holdings, Llc	10 percent owner	506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Bruce Culleton	officer: EVP, Clinical Development	2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM NC 27103
Aaron Cowen	10 percent owner	540 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Mary Weger	officer: Chief People Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
William F Doyle	director
Tolerantia, Llc	10 percent owner	110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022
Jimenez Santos Jose Ignacio	director	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Deepak Jain	officer: Chief Operating Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Darin J. Weber	officer: SVP of Regulatory Development	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Libbie Parker Mckenzie	officer: Chief Medical Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
James Coulston	officer: Chief Financial Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Jennifer A. Fox	director	C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Timothy Bertram	director, officer: Chief Executive Officer	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403